Naltrexone + bupropion
Naltrexone + bupropion has been studied in 46 papers since 2022: 2 trials and 11 observational studies in people, 1 in animals, 31 reviews; 24 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Weight-Loss-Enriched Reverse Cardiac Remodeling After Semaglutide and Tirzepatide Initiation on Longitudinal Echocardiography”.
46 papers study it13 more mention it11 findingsUpdated
4 new papers in 30 daysSee all 59 papers on naltrexone + bupropion
At a glance
Independent labs found the same change in people. 5 independent labs in 4 countries; 31 trials, none about aging, 6 with no results posted.
“56-week weight loss was significantly greater with NB-ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003)”
None of its findings points the other way.
- 5 independent labs in 4 countries
- 31 trials, none about aging, 6 with no results posted
- Funders: Centro de Investigación en Red en Enfermedades Cardiovasculares and 6 more
- 5 of 10 findings with company ties
- 11 of 31 trials sponsored by its developers
- Human trial2
- Humans11
- Animals1
- In silico1
Studies in people
1 study gave naltrexone + bupropion to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases body weight5.7% ± 0.6% vs 2.7% ± 0.8% no change: Has no effect on psychiatric adverse events27.5% vs 22.1% | Review of trials56 weeks | 511 people pooled87% were femaleParticipants with baseline symptoms of depression | Obesity (Silver Spring, Md.), Mar 31, 2026 |
What did studies of naltrexone + bupropion find?
5Studies of naltrexone + bupropion measured 5 outcomes; the most studied is body weight (3 studies).
Body weight
downin humans2downin reviews1−6% loss of starting total body weight
3 studies
Body weight
downin humans2downin reviews1−6% loss of starting total body weight
Naltrexone + bupropion decreases body weight in humans (5.7% ± 0.6% vs 2.7% ± 0.8%).
“From baseline to Week 56, participants assigned to NB‐ER had a significantly greater mean (±SE) percent reduction in body weight of 5.7% ± 0.6% (95% CI: 4.6%–6.9%) compared to the 2.7% ± 0.8% (95% CI: 1.1%–4.4%) reduction in the placebo group”
Human trial56 weeksn = 511
Obesity (Silver Spring, Md.)
Naltrexone + bupropion decreases body weight in humans (overweight/obesity and mild to moderate symptoms of depression) (5.7% ± 0.6% vs. 2.7% ± 0.8%).
“56-week weight loss was significantly greater with NB-ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003)”
Human trialoverweight/obesity and mild to moderate symptoms of depressionextended-release56 weeks
Obesity (Silver Spring, Md.)
Naltrexone + bupropion decreases body weight in humans (-5.60 [-8.64 to -2.56] kg).
“Naltrexone-bupropion, GLP-1 receptor agonists, SGLT-2 inhibitors, and metformin were found to reduce body weight (-5.60 [-8.64 to -2.56] kg”
Review
Obesity reviews : an official journal of the International Association for the Study of Obesity
Naltrexone + bupropion decreases body weight (~6% loss of starting total body weight).
“Clinical trials report ~ 6% loss of starting total body weight with use of Contrave”
Review
Reproductive biology and endocrinology : RB&E
Psychiatric adverse events
no changein humans1
1 study
Psychiatric adverse events
no changein humans1
Naltrexone + bupropion showed no clear effect on psychiatric adverse events in humans (27.5% vs 22.1%).
“PAEs occurred in 27.5% of participants treated with NB‐ER and 22.1% of those treated with placebo, with no significant difference between the groups in overall incidence.”
Human trial56 weeksn = 511
Obesity (Silver Spring, Md.)
Naltrexone + bupropion showed no clear effect on psychiatric adverse events in humans (overweight/obesity and mild to moderate symptoms of depression) (27.5% vs. 22.1%).
“NB-ER and placebo did not differ in safety signals including PAE occurrence (27.5% NB-ER vs. 22.1% placebo), depressive symptom increases (9.5% NB-ER vs. 8.8% placebo), or suicidal ideation (1.8% NB-ER vs. 2.0% placebo).”
Human trialoverweight/obesity and mild to moderate symptoms of depressionextended-release56 weeks
Obesity (Silver Spring, Md.)
Depression
no changein humans1
1 study
Depression
no changein humans1
Naltrexone + bupropion showed no clear effect on depression in humans (overweight/obesity and mild to moderate symptoms of depression) (-7.1 ± 0.4 vs. -6.7 ± 0.5).
“Participants experienced clinically meaningful improvements in depression of -7.1 ± 0.4 with NB-ER and -6.7 ± 0.5 with placebo, with no significant differences between the groups.”
Human trialoverweight/obesity and mild to moderate symptoms of depressionextended-release56 weeks
Obesity (Silver Spring, Md.)
Emotional eating
downin humans1
1 study
Emotional eating
downin humans1
Naltrexone + bupropion is linked with lower emotional eating in humans (early responders (≥5% weight loss at 3 months)) (dz 2.04).
“emotional eating reductions with naltrexone/bupropion (dz 2.04)”
Humansearly responders (≥5% weight loss at 3 months)6 months
Preprints.orgPreprint
Ki67
no changein rats1
1 study
Ki67
no changein rats1
Naltrexone + bupropion showed no clear effect on Ki67 in rats (obese type 2 diabetes).
“while NTX + BUP showed insignificant effects.”
Animalsobese type 2 diabetesorally4 mg/45 mg /kg/daymales
Journal of molecular histology
What is naltrexone + bupropion linked with?
2Studies link naltrexone + bupropion with 2 measures: suicide attempt and suicidal ideation.
Suicide attempt
upin humans1
1 study
Suicide attempt
upin humans1
Naltrexone + bupropion is associated with suicide attempt in humans (disproportionality analysis of FAERS reports) (ROR 4.11 (95% CI 1.62-10.45)).
“Naltrexone/bupropion showed elevated disproportional reporting for suicidal ideation (ROR 3.84; 95% CI 2.89-5.12) and suicide attempt (ROR 4.11; 95% CI 1.62-10.45.”
Humansdisproportionality analysis of FAERS reports
International journal of clinical pharmacy
Suicidal ideation
upin humans1
1 study
Suicidal ideation
upin humans1
Naltrexone + bupropion is associated with suicidal ideation in humans (disproportionality analysis of FAERS reports) (ROR 3.84 (95% CI 2.89-5.12)).
“Naltrexone/bupropion showed elevated disproportional reporting for suicidal ideation (ROR 3.84; 95% CI 2.89-5.12) and suicide attempt (ROR 4.11; 95% CI 1.62-10.45.”
Humansdisproportionality analysis of FAERS reports
International journal of clinical pharmacy
Has naltrexone + bupropion been tested in people?
0 of 31 about agingYes: 2 trials and 11 observational studies in people have been published, and 31 trials are registered.
Approved
Sep 10, 2014obesity or overweight, excess body weight
Mar 26, 2015Obesity, Overweight
Repurposing
Phase 4Terminated1 trial
Phase 4Terminated3 trials
Phase 4Results posted2 trials
Phase 4Recruiting1 trial
Phase 4Recruiting1 trial
Phase 4Recruiting1 trial
All 16Fewer
In trials
Cigarette smoking
Phase 4Results posted1 trial
Heart repolarization
Phase 1Completed1 trial
Stopped
NCT04531176TerminatedObesity
After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.
NCT03132571TerminatedDiabetes mellitus
Study discontinued due to funding.
NCT06374290TerminatedSmoking cessation
Unable to recruit eligible participants and expiration of study medication.
Trial sponsors
Company11 trialsPhase 45,228 people
St. Joseph's Healthcare Hamilton
2 trialsPhase 4107 people
1 trialPhase 4108 people
1 trialPhase 4100 people
1 trialPhase 474 people
1 trialPhase 422 people
National Institute on Drug Abuse
1 trialPhase 3360 people
5 trialsPhase 2/3164 people